Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
Summary
The bill renews a program aimed at getting important treatments to people with amyotrophic lateral sclerosis (ALS) more quickly. It affects ALS patients, their doctors, and researchers by trying to reduce delays in therapy availability. The measure is intended to improve health outcomes for those living with this progressive disease.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 8205 changes status, plus AI-powered summaries and stage predictions.
Sign up free